KOL Perspectives: JAK Inhibitor Safety in IBD
- GDHC012SP
- Pages: 31
- May 2018
- Total Views:1136
- Region : Global
- GlobalData
- Market Research Report

Details
KOL Perspectives: JAK Inhibitor Safety in IBD
Summary
This KOL Insight briefing focuses on the potential use of selective JAK inhibitors in IBD.
The briefing includes analysis of KOL opinion on the following topic areas-
- Maintenance data for selective JAKs in Crohn's disease
- Differentiating strategies for selective and non-selective JAKs in IBD
- Choice of primary endpoints for IBD trials
- Selective JAKs' expected efficacy in UC
- Real-world use of JAKs in IBD
Key Highlights
- KOLs are broadly positive about TOF's safety profile in UC, highlighting TOF's relative comparability to safety seen in other indications
- Most KOLs view the majority of JAK inhibitors in development in IBD as has having similar safety profiles, regardless of JAK-selectivity
- Most KOLs agree that patients should ideally be vaccinated before immunosuppressant treatment, however, reimbursement remains a significant barrier that can restrict vaccination to during treatment.
Scope
- The insight briefing is based on Sociable Pharma's analysis of primary research with our 10 key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 US-based
- Interviews performed during March 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "JAK Inhibitor Safety in IBD"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Table Of Content
Scope
Table of Contents
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
JAK inhibitor, IBD, safety
Companies
Pfizer
Gilead
Galapagos
GSK
AbbVie
Company Profile
Company Profile Title
KOL Perspectives: JAK Inhibitor Safety in IBD
Summary
This KOL Insight briefing focuses on the potential use of selective JAK inhibitors in IBD.
The briefing includes analysis of KOL opinion on the following topic areas-
- Maintenance data for selective JAKs in Crohn's disease
- Differentiating strategies for selective and non-selective JAKs in IBD
- Choice of primary endpoints for IBD trials
- Selective JAKs' expected efficacy in UC
- Real-world use of JAKs in IBD
Key Highlights
- KOLs are broadly positive about TOF's safety profile in UC, highlighting TOF's relative comparability to safety seen in other indications
- Most KOLs view the majority of JAK inhibitors in development in IBD as has having similar safety profiles, regardless of JAK-selectivity
- Most KOLs agree that patients should ideally be vaccinated before immunosuppressant treatment, however, reimbursement remains a significant barrier that can restrict vaccination to during treatment.
Scope
- The insight briefing is based on Sociable Pharma's analysis of primary research with our 10 key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 US-based
- Interviews performed during March 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "JAK Inhibitor Safety in IBD"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Scope
Table of Contents
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
JAK inhibitor, IBD, safety
Companies
Pfizer
Gilead
Galapagos
GSK
AbbVie